** Shares of ophthalmic medical device company RxSight RXST.O fall 33% to $8.55 in extended trading

** RXST cut its 2025 sales forecast to the range of $120 million to $130 million, vs prior expectation of $160 million to $175 million

** Analysts, on average, expect 2025 sales to reach $167.6 million, according to data compiled by LSEG

** Company also expects preliminary Q2 sales to be about $33.6 million, below analysts' estimates of $39.8 million

** J.P. Morgan analysts say the company's update reflects a "continued worsening of trends first seen last quarter rather than a hopeful improvement, a concerning trend set to continue into 2H25 with no clear resolution in sight"

** Stock down 62.8%, YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))